CN101094647A - 非诺贝特与脂肪酸酯的稳定组合物 - Google Patents

非诺贝特与脂肪酸酯的稳定组合物 Download PDF

Info

Publication number
CN101094647A
CN101094647A CNA2005800454249A CN200580045424A CN101094647A CN 101094647 A CN101094647 A CN 101094647A CN A2005800454249 A CNA2005800454249 A CN A2005800454249A CN 200580045424 A CN200580045424 A CN 200580045424A CN 101094647 A CN101094647 A CN 101094647A
Authority
CN
China
Prior art keywords
fatty acid
acid ester
fenofibrate
pharmaceutical composition
omega
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800454249A
Other languages
English (en)
Chinese (zh)
Inventor
乔治·博博泰斯
鲁洛夫·M.·L.·龙根
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reliant Pharmaceuticals Inc
Original Assignee
Reliant Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reliant Pharmaceuticals Inc filed Critical Reliant Pharmaceuticals Inc
Publication of CN101094647A publication Critical patent/CN101094647A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CNA2005800454249A 2004-12-06 2005-12-05 非诺贝特与脂肪酸酯的稳定组合物 Pending CN101094647A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63312604P 2004-12-06 2004-12-06
US60/633,126 2004-12-06

Publications (1)

Publication Number Publication Date
CN101094647A true CN101094647A (zh) 2007-12-26

Family

ID=36578470

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800454249A Pending CN101094647A (zh) 2004-12-06 2005-12-05 非诺贝特与脂肪酸酯的稳定组合物

Country Status (12)

Country Link
US (1) US20060188529A1 (https=)
EP (1) EP1830804A2 (https=)
JP (1) JP2008522972A (https=)
KR (1) KR20070098855A (https=)
CN (1) CN101094647A (https=)
AU (1) AU2005314197A1 (https=)
BR (1) BRPI0518426A2 (https=)
CA (1) CA2589656A1 (https=)
EA (1) EA200701228A1 (https=)
MX (1) MX2007006775A (https=)
NO (1) NO20073457L (https=)
WO (1) WO2006062933A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006017692A2 (en) * 2004-08-06 2006-02-16 Transform Pharmaceuticals, Inc. Novel fenofibrate formulations and related methods of treatment
CN101098690A (zh) * 2004-12-06 2008-01-02 瑞莱恩特医药品有限公司 用于血脂治疗的ω-3脂肪酸和脂血异常剂
CA2746887C (en) 2008-12-15 2016-07-05 Banner Pharmacaps, Inc. Methods for enhancing the release and absorption of water insoluble active agents
KR101746867B1 (ko) * 2009-01-26 2017-06-14 타이페이 메디컬 유니이버시티 당뇨 및 비만을 치료하기 위한 프테로신 화합물의 용도
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
WO2013192109A1 (en) 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5545628A (en) * 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
MY118354A (en) * 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
FR2737121B1 (fr) * 1995-07-27 1997-10-03 Cl Pharma Nouvelles formulations galeniques du fenofibrate et leurs applications
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US6117911A (en) * 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
WO1999029316A1 (en) * 1997-12-10 1999-06-17 Severson, Mary, L. Pharmaceutical compositions containing an omega-3 fatty acid oil
CA2355820A1 (en) * 1998-12-18 2000-06-29 Abbott Laboratories Novel formulations comprising lipid-regulating agents
US6814977B1 (en) * 1998-12-18 2004-11-09 Abbott Laboratories Formulations comprising lipid-regulating agents
US7014864B1 (en) * 1998-12-18 2006-03-21 Abbott Laboratories Formulations comprising lipid-regulating agents
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
HK1044704A1 (zh) * 1999-03-31 2002-11-01 Abbott Laboratories 含有脂调节剂的新配方
US6372251B2 (en) * 1999-06-11 2002-04-16 Abbott Laboratories Formulations comprising lipid-regulating agents
US6982281B1 (en) * 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
FR2803203B1 (fr) * 1999-12-31 2002-05-10 Fournier Ind & Sante Nouvelles formulations galeniques du fenofibrate
US6667064B2 (en) * 2000-08-30 2003-12-23 Pilot Therapeutics, Inc. Composition and method for treatment of hypertriglyceridemia
FR2818905A1 (fr) * 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
US20040005339A1 (en) * 2002-06-28 2004-01-08 Shojaei Amir H. Formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability

Also Published As

Publication number Publication date
CA2589656A1 (en) 2006-06-15
KR20070098855A (ko) 2007-10-05
WO2006062933A3 (en) 2006-08-31
US20060188529A1 (en) 2006-08-24
WO2006062933A2 (en) 2006-06-15
MX2007006775A (es) 2008-02-25
AU2005314197A1 (en) 2006-06-15
BRPI0518426A2 (pt) 2008-11-25
EA200701228A1 (ru) 2007-12-28
JP2008522972A (ja) 2008-07-03
EP1830804A2 (en) 2007-09-12
NO20073457L (no) 2007-09-05

Similar Documents

Publication Publication Date Title
CN101098688A (zh) 用Omega-3脂肪酸和PPAR激动剂和/或拮抗剂治疗及其组合产品
US10668038B2 (en) Emulsion and emulsion preconcentrate compositions comprising omega-3 fatty acids and uses thereof are disclosed
EP2519230B1 (en) Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
Fricker et al. Phospholipids and lipid-based formulations in oral drug delivery
JP7394974B2 (ja) 酢酸アビラテロンを含む医薬組成物、並びにその製造方法及び使用
JP4831965B2 (ja) ＨＭＧ−ＣｏＡ還元酵素インヒビター誘導体（「スタチン」）を含むナノ粒子製剤、その新規組合せ、ならびにこれらの医薬組成物の製造
TWI694823B (zh) 含有脂質化合物、三酸甘油酯及界面活性劑之組成物與使用該組成物之方法
US6416793B1 (en) Formulations and use of controlled-release indole alkaloids
CN101252837A (zh) 用二氢吡啶类钙通道阻断剂和Omega-3脂肪酸及其组合产品的治疗
AU2015222880A1 (en) Controlled release enteric soft capsules of fumarate esters
EP2613766A2 (en) Compositions comprising a fatty acid oil mixture comprising epa and dha in free acid form, a surfactant, and a statin
AU2005271407A1 (en) Novel fenofibrate formulations and related methods of treatment
JP2010506841A (ja) 抗不整脈薬およびオメガ−３脂肪酸およびそれらの組合せ品による治療法
US20160151392A1 (en) Self-nanoemulsion of poorly soluble drugs
CN101094647A (zh) 非诺贝特与脂肪酸酯的稳定组合物
JP2009544701A (ja) オメガ３脂肪酸を含む組成物、ならびに末梢動脈障害および間欠性跛行を処置するためのそれらの使用
EP3735296A1 (en) Natural combination products and methods for regulation of total blood cholesterol
JP6783891B2 (ja) ω３脂肪酸の自己乳化組成物
JP2010229099A (ja) 脂質異常症の改善または治療薬
CN110115766B (zh) 一种含有氟比洛芬酯的复方制剂及其制备方法
CA2538494C (en) Composition for modulating blood parameters
JP2021008518A (ja) ω３脂肪酸の自己乳化組成物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20071226